Fluorescence-guided pelvic lymphadenectomy in prostate cancer: Restrospective analysis of diagnostic accuracy and oncologic outcomes

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039524

Enrollment

450

Registered

2026-03-09

Start date

2025-10-02

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: prostate cancer patients who underwent radical prostatectomy and fluorescence-guided pelvic lymphadenectomy

retrospective collection of data on diagnostic accuracy of lymph node marking with reference to extended pelvic lymphadenectomy from histopathology reports as well as collection of oncologic follow up

retrospective data collection as in arm 1 Group 3: prostate cancer patients who underwent radical prostatectomy and extended pelvic lymphadenectomy

retrospective data collection as in arm 1

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Prostate cancer patients who underwent radical prostatectomy and fluorescence- or magnetometer-guided pelvic lymphadenectomy in combination with risk-adjusted extended pelvic lymphadenectomy or risk-adjusted pelvic lymphadenectomy alone at the University Hospital for Urology, Klinikum Oldenburg, Germany, between 01.02.2022 and 05.02.2025.

Exclusion criteria

Exclusion criteria: - patients with prior prostate surgery or with anti-hormonal treatment before radical prostatectomy - cases with incomplete data - patients unable to consent

Design outcomes

Primary

Measure	Time frame
sensitivity and specificity of fluorescence-guided pelvic lymphadenectomy (index test) with extended pelvic lymphadenectomy as reference; restrospective data collection from histopathology reports	—

Secondary

Measure	Time frame
1. sensitivity and specificity of magnetometer-guided pelvic lymphadenectomy (index test) with extended pelvic lymphadenectomy as reference 2. 5-year-probabilities of biochemical recurrence, start of adjuvant therapy and overall mortality after fluorescence- or magnetometer-guided or extended pelvic lymphadenectomy alone	—

Countries

Germany

Contacts

Public ContactAlexander Winter

Universitätsklinik für Urologie, Klinikum Oldenburg, Carl von Ossietzky Universität Oldenburg

winter.alexander@klinikum-oldenburg.de+494414032302

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026